UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
August 5, 2005
Commission File Number 0-21392
AMARIN CORPORATION PLC
(Translation of registrant's name into English)
7 Curzon Street
London W1J 5HG
England
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
Attachment:
Material Events
(a) Amarin Corporation announces appointment of Dr. Prem Lachman as non-
executive director.
This report on Form 6-K is hereby incorporated by reference
in (a) the registration statement on Form F-3 (Registration No.
333-104748) of Amarin Corporation plc and in the prospectus
contained therein, (b) the registration statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc and in the
prospectus contained therein, (c) the registration statement on
Form F-3 (Registration No. 333-12642) of Amarin Corporation plc and
in the prospectus contained therein, (d) the registration statement
on Form F-3 (Registration No. 333-121431) of Amarin Corporation plc and
in the prospectus contained therein and (e) the registration statement
on Form F-3 (Registration No. 333-121760) of Amarin Corporation plc and
in the prospectus contained therein, and this report on Form 6-K
shall be deemed a part of each such registration statement from the
date on which this report is filed, to the extent not superseded by
documents or reports subsequently filed or furnished by Amarin
Corporation plc under the Securities Act of 1933 or the Securities
Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By: /s/ Jonathan Lamb
Name: Jonathan Lamb
Title: Secretary
Date: August 5, 2005
EXHIBIT INDEX
Index to Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material event description 4
AMARIN ANNOUNCES APPOINTMENT OF DR. PREM LACHMAN TO BOARD OF DIRECTORS
LONDON, United Kingdom, August 4, 2005 - Amarin Corporation plc
(NASDAQSC: AMRN) today announced the appointment of Dr. Prem Lachman as non-
executive director.
Dr. Lachman is founder and general partner of Maximus Capital, a $100 million
healthcare investment management company focused on investments in the
biotechnology and pharmaceutical industries. Dr. Lachman was formerly a general
partner at the Galleon Group from 1998 until 2001 and prior to that was a
managing director in the Investment Research Department at Goldman Sachs & Co.
Dr. Lachman received his M.D. degree from the Mount Sinai School of Medicine in
May 1986.
Rick Stewart, Chief Executive Officer of Amarin, commented "We very much welcome
Prem to the board of Amarin - his in-depth knowledge and experience will be
invaluable to the company as we drive our business forward."
Contact:
Amarin Corporation plc +44 (0) 207 907 2442
Rick Stewart Chief Executive Officer
Alan Cooke Chief Financial Officer
investor.relations@amarincorp.com
Powerscourt +44 (0) 207 236 5615
Rory Godson/Victoria Brough
About Amarin Corporation
Amarin Corporation plc is a neuroscience company focused on the development and
commercialization of novel drugs for the treatment of central nervous system
disorders. Miraxion, Amarin's lead development compound, is in phase III
development for Huntington's disease and in phase II development for treatment-
unresponsive depression.
For press releases and other corporate information, visit our website at
http://www.amarincorp.com.
Statements in this press release that are not historical facts are forward-
looking statements that involve risks and uncertainties which may cause the
Company's actual results in future periods to be materially different from any
performance suggested herein. Such risks and uncertainties include, without
limitation, the inherent uncertainty of pharmaceutical research, product
development and commercialization, the impact of competitive products and
patents, as well as other risks and uncertainties detailed from time to time in
periodic reports. For more information, please refer to Amarin Corporation's
Annual Report for 2004 on Form 20-F and its Form 6-Ks as filed with the U.S.
Securities and Exchange Commission. The Company assumes no obligation to update
information on its expectations.